Placebo BID: Clinical Trials

12 trials of Placebo BID, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 recruiting, 2 unknown, 1 terminated. 6 Phase 2, 6 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 26Completed 2, Unknown 2, Recruiting 1, Terminated 1
Phase 36Completed 4, Recruiting 1, Unknown 1
Phase 41Completed 1

Follow Placebo BID: new trials by email Literature Review of Placebo BID trials Research Report on Placebo BID

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID - Demodex Blepharitis
Phase 2RecruitingGlaukos Corporation2502025-12-052026-02-27
Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
ACER-002 (celiprolol) 200 mg BID, Placebo BID - Vascular Ehlers-Danlos Syndrome
Phase 3RecruitingAcer Therapeutics Inc.1502022-11-072025-08-24
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg - Sickle Cell Disease
Phase 2CompletedVifor (International) Inc.252021-11-182025-02-18
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
HSK16149 20mg BID, HSK16149 40mg BID, Placebo BID - Postherpetic Neuralgia
Phase 3CompletedHaisco Pharmaceutical Group Co., Ltd.3722021-11-012023-02-27
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial
Apixaban, Placebo - Heart Failure, Sinus Rhythm
Phase 2UnknownKorea University Guro Hospital2002021-03-022021-01-20
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain
HSK16149 20mg BID, HSK16149 40mg BID, HSK16149 60mg BID - Diabetic Peripheral Neuropathic Pain
Phase 2 / Phase 3UnknownHaisco Pharmaceutical Group Co., Ltd.6872020-12-022020-12-01
Efficacy and Safety of SOM3355 in Huntington's Disease Chorea
SOM3355 100mg BID, SOM3355 200mg BID, Placebo BID - Huntington's Chorea
Phase 2CompletedSOM Innovation Biotech SA322018-08-082019-09-16
Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis
Budesonide 0.5mg orodispersible tablet twice daily, Budesonide 1mg orodispersible tablet twice daily, Placebo orodispersible tablet twice daily - Eosinophilic Esophagitis
Phase 3CompletedDr. Falk Pharma GmbH2042016-01-152021-10-07
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 3CompletedInotek Pharmaceuticals Corporation3032015-09-012016-12-06
Topical Ibuprofen for Delayed Onset Mulscle Soreness
IBU BID, Placebo BID, IBU TID - Pain
Phase 3CompletedPfizer2052013-06-132021-09-30
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID - Diabetes Mellitus
Phase 2TerminatedN-Gene Research Laboratories, Inc.1962010-10-012014-09-29
Seizures Post Intracerebral Hemorrhage
valproic acid, placebo bid - Post Cerebral Hemorrhage
Phase 4CompletedWolfson Medical Center722003-02-012014-06-12

Conditions studied

Anemia (1)  ·  Anemia, Sickle Cell (1)  ·  Cerebrovascular Disorders (1)  ·  Chorea (1)  ·  Diabetes Mellitus (1)  ·  Ehlers-Danlos Syndrome, Type IV (1)  ·  Eosinophilic Esophagitis (1)  ·  Glaucoma (1)  ·  Glaucoma, Open-Angle (1)  ·  Heart Failure (1)  ·  Huntington Disease (1)  ·  Neuralgia, Postherpetic (1)  ·  Ocular Hypertension (1)  ·  Pain (1)

Sponsors

Haisco Pharmaceutical Group Co., Ltd. (2)  ·  Acer Therapeutics Inc. (1)  ·  Dr. Falk Pharma GmbH (1)  ·  Glaukos Corporation (1)  ·  Inotek Pharmaceuticals Corporation (1)  ·  Korea University Guro Hospital (1)  ·  N-Gene Research Laboratories, Inc. (1)  ·  Pfizer (1)  ·  SOM Innovation Biotech SA (1)  ·  Vifor (International) Inc. (1)  ·  Wolfson Medical Center (1)

Countries

United States (6)  ·  China (2)  ·  Germany (2)  ·  France (1)  ·  Greece (1)  ·  Hungary (1)  ·  Lebanon (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Cadmus C Rich, MD,MBA,CPE (1)  ·  Eung Ju Kim, MD, PhD. (1)  ·  Ioanna Gouni-Berthold, MD (1)  ·  Laszlo Koranyi, MD (1)  ·  Peter Damsbo, MD (1)  ·  Ralph Mueller, PhD (1)  ·  Ricardo Hermosilla, PhD (1)  ·  Robert Ratner, MD (1)

Results publications

PMID 36494329, PMID 39158916, PMID 39320907, PMID 39659429, PMID 39694205, PMID 40377855

NIH funding

2009 (1), 2014 (1), 2018 (1)